The Global Plant Tissue Culture Market size is expected to be worth around US$ 1.2 Billion by 2034, from US$ 0.5 Billion in 2024, growing at a CAGR of 9.2% during the forecast period from 2025 to 2034.
In 2025, the Plant Tissue Culture Market is expanding into pharmaceutical and high-value bioproduct production. Root and cell suspension cultures are being explored for mass-scale synthesis of plant-derived recombinant proteins, vaccines, and secondary metabolites such as taxanes and paclitaxel. Bioreactor systems produce consistent, scalable batches of rare therapeutic compounds without field cultivation.
Contract manufacturing plants supply biotech firms developing plant-based biologics. Meanwhile, metabolite-focused cultures support cosmetic and nutraceutical industries with standardized extracts. These shifts are turning plant tissue culture into a robust platform for plant-based biomanufacturing, reducing reliance on wild harvesting and enabling GMP-grade production.
Click here for more information: https://market.us/report/plant-tissue-culture-market/
Emerging Trends
Cell suspension bioreactors producing therapeutic proteins and monoclonal antibodies.
Hairy root cultures for high-yield secondary metabolites like paclitaxel.
GMP-based plant cell culture facilities for commercial extract manufacturing.
Cosmetic and nutraceutical extract standardization through controlled culture conditions.
Use Cases
A biopharma firm uses tobacco cell cultures to produce recombinant vaccine antigens with high purity.
A contract culture facility runs hairy root bioreactors to supply paclitaxel for oncology drugs.
A skincare brand sources glycoside-rich extracts grown via tissue culture under GMP standards.
A nutraceutical company uses root cultures to produce antioxidant-rich compounds with consistent bioactivity.
Leave a comment